Novel pharmaceutical molecules against emerging resistant gram-positive cocci

Brazilian Journal of Infectious Diseases

Volumn 14, Issue 1, 2010, Pages 96-108

  Manfredi, Roberto ^a   Sabbatani, Sergio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Characteristics; Clinical issues; Enterococci; Epidemiology; Literature evidences; Novel antimicrobial compounds; Pneumococci; Resistant gram positive cocci; Staphylococci; Streptococci

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM; CARBAPENEM DERIVATIVE; CEFAZOLIN; CLINDAMYCIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DIGOXIN; GENTAMICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LINEZOLID; LUNG SURFACTANT; ORITAVANCIN; OXACILLIN; PYRIDOXINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN; WARFARIN;

ABDOMINAL INFECTION; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ANTIBIOTIC RESISTANCE; ARTHRALGIA; BACTEREMIA; BACTERICIDAL ACTIVITY; BONE INFECTION; BONE MARROW TOXICITY; BRAIN ABSCESS; CATHETER INFECTION; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL SKIN REACTION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CREATINE KINASE BLOOD LEVEL; DECUBITUS; DIABETIC FOOT; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; ENDOCARDITIS; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE INFECTION; GRAM POSITIVE COCCI; GRAM POSITIVE INFECTION; HEARTBURN; HOSPITAL INFECTION; HUMAN; HYPOKALEMIA; INFECTION PREVENTION; INFECTIOUS ARTHRITIS; ITALY; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER DISEASE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NONHUMAN; OPTIC NERVE DISEASE; OSTEOMYELITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PHLEBITIS; PNEUMOCOCCAL MENINGITIS; PNEUMONIA; PROSTHESIS INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS; SEPTICEMIA; SEROTONIN SYNDROME; SHUNT INFECTION; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; SURGICAL INFECTION; TASTE DISORDER; TERTIARY HEALTH CARE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VASCULITIS; VOMITING;

EID: 77954833270     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1413-86702010000100020     Document Type: Review

References (107)

1. Foster JK, Lentino JR, Strodtman R, DiVincenzo C. Comparison of in vitro activity of quinolone antibiotics and vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus by time-kill kinetic studies. Antimicrob Agents Chemother 1986;30:823-7.
2. Tallent SM, Bischoff T, Climo M, Ostrowsky B, Wenzel RP, Edmond MB. Vancomycin susceptibility of oxacillin-resistant Staphylococcus aureus isolates causing nosocomial bloodstream infections. J Clin Microbiol 2002; 40:2249-50.
3. Sieradzki K, Leski T, Dick J, Borio L, Tomasz A. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J Clin Microbiol 2003; 41:1687-93.
4. Murray BE. Vancomycin-resistant enterococci. Am J Med 1997; 102:284-93.
5. Okuma K, Iwakawa K, Turnidge JD et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol 2002; 40:4289-94.
6. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987; 316:927-31.
7. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135-6.
8. Appelbaum PC. MRSA-the tip of the iceberg. Clin Microbiol Infect 2006; 12 Suppl 2:3-10.
9. MMWR. Staphylococcus aureus resistant to vancomycin-United States 2002. Vol. 51 (26): 565.567RE, 2002.
10. Chang S, Sievert DM, Hageman JC et al. Infection with vancomycin-resistant taphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342-7.
11. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the redominant cause of skin and soft-tissue infections. Ann Intern Med 2006;144:309-17.
12. Moellering RC, Jr. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med 2006; 144:368-70.
13. Noskin GA, Rubin RJ, Schentag JJ et al. The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med 2005; 165:1756-61.
14. Rupp ME, Archer GL. Coagulase-negative Staphylococci: pathogens associated with medical progress. Clin Infect Dis 1994; 19:231-43; quiz 244-5.
15. Schaaff F, Reipert A, Bierbaum G. An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46:3540-8.
16. Chang FY, Peacock JE, Jr, Musher DM et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82:333-9.
17. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117:390-8.
18. Becker K, Friedrich AW, Lubritz G, Weilert M, Peters G, Von Eiff C. Prevalence of genes encoding pyrogenic toxin superantigens and exfoliative toxins among strains of Staphylococcus aureus isolated from blood and nasal specimens. J Clin Microbiol 2003;41:1434-9.
19. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520-32.
20. Sakoulas G, Moellering RC, Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 2006; 42 Suppl 1:S40-50.
21. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15:167-93.
22. Caiazza NC, O'Toole GA. Alpha-toxin is required for biofilm formation by Staphylococcus aureus. J Bacteriol 2003; 185:3214-7.
23. von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative Staphylococci. Lancet Infect Dis 2002; 2:677-85.
24. Yu VL, Chiou CC, Feldman C et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37:230-7.
25. Peterson LR. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter? Clin Infect Dis 2006; 42:224-33.
26. Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35:556-64.
27. Schentag JJ, Klugman KP, Yu VL et al. Streptococcus pneumoniae bacteremias: pharmacodynamic correlations with outcome and macrolide resistance: a controlled study. Int J Antimicrob Agents 2007; 30:264-9.
28. Greenberg D DR, Klugman K, Madhi SA et al. Streptococcus pneumoniae serotypes causing meningitis in children and adults. Proceedings of the 14th ICAAC Conference. Washington, DC., 2004.
29. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38:994-1000.
30. Fenton C, Keating GM, Curran MP. Daptomycin. Drugs 2004; 64:445-55.
31. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Grampositive infections. J Antimicrob Chemother 2005; 55:283-8.
32. Schriever CA, Fernandez C, Rodvold KA, Danziger LH. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm 2005; 62:1145-58.
33. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138:135-42.
34. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrugresistant, gram-positive infections: experience from a compassionate- use program. Clin Infect Dis 2003; 36:159-68.
35. LaPlante KL, Rybak MJ. Daptomycin - a novel antibiotic against Gram-positive pathogens. Expert Opin Pharmacother 2004; 5:2321-31.
36. Jeu L, Fung HB. Daptomycin: a cyclic lipopeptide antimicrobial agent. Clin Ther 2004; 26:1728-57.
37. Alder JD. Daptomycin: a new drug class for the treatment of Gram-positive infections. Drugs Today (Barc) 2005; 41:81-90.
38. Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005; 56:611-4.
39. Pankey GA. Tigecycline. J Antimicrob Chemother 2005; 56:470-80.
40. Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 2004; 64:913-36.
41. Virginlar N. MA. Glycopeptides (Dalbavancin, Oritavancin, Teicoplanin, Vancomycin). In: Yu VL, Eds. Antimicrobial Therapy and Vaccines. Vol. II: Antimicrobial Agents: www.antimicrobe.org, 2004.
42. Hershberger E, Donabedian S, Konstantinou K, Zervos MJ. Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis 2004; 38:92-8.
43. Speciale A, La Ferla K, Caccamo F, Nicoletti G. Antimicrobial activity of quinupristin/dalfopristin, a new injectable streptogramin with a wide Gram-positive spectrum. Int J Antimicrob Agents 1999; 13:21-8.
44. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999; 44:251-61.
45. Nichols RL, Graham DR, Barriere SL et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999; 44:263-73.
46. Meka VG, Pillai SK, Sakoulas G et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 2004; 190:311-7.
47. Fagon J, Patrick H, Haas DW et al. Treatment of grampositive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000; 161:753-62.
48. Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000; 46:775-84.
49. Carver PL, Whang E, VandenBussche HL, Kauffman CA, Malani PN. Risk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy. Pharmacotherapy 2003; 23:159-64.
50. Raad I, Hachem R, Hanna H. Relationship between myalgias/arthralgias occurring in patients receiving quinupristin/dalfopristin and biliary dysfunction. J Antimicrob Chemother 2004; 53:1105-8.
51. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42:1129-40.
52. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260-6.
53. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-12.
54. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two doubleblind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-97.
55. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42:1411-23.
56. Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 2004; 32:8-14.
57. Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopedic infections. Mayo Clin Proc 2004; 79:1137-44.
58. Cook AM, Ramsey CN, Martin CA, Pittman T. Linezolid for the treatment of a heteroresistant Staphylococcus aureus shunt infection. Pediatr Neurosurg 2005; 41:102-4.
59. Rho JP, Sia IG, Crum BA, Dekutoski MB, Trousdale RT. Linezolid-associated peripheral neuropathy. Mayo Clin Proc 2004; 79:927-30.
60. Spellberg B, Yoo T, Bayer AS. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother 2004; 54:832-5.
61. Young LS. Hematologic effects of linezolid versus vancomycin. Clin Infect Dis 2004; 38:1065-6.
62. Rao N, Ziran BH, Wagener MM, Santa ER, Yu VL. Similar hematologic effects of longterm linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis 2004; 38:1058-64.
63. Nasraway SA, Shorr AF, Kuter DJ, O'Grady N, Le VH, Cammarata SK. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 2003; 37:1609-16.
64. Kulkarni K, Del Priore LV. Linezolid induced toxic optic neuropathy. Br J Ophthalmol 2005; 89:1664-5.
65. Narita MT, B Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosid and serotonin syndrome: a review. Pharmacotherapy 2007; 27:1189-97.
66. Soriano A, Miro O, Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med 2005; 353:2305-6.
67. Bernard L, Stern R, Lew D, Hoffmeyer P. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis 2003; 36:1197.
68. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-81.
69. Fowler VG, Cosgrove S. Abrutyn E, et al. Daptomycin vs. Standard Therapy for Staphylococcus aureus Bacteremia (SAB) and Infective Endocarditis (SAIE). 45th Annual Interscience Congress on Antimicrobial Agents and Chemotherapy. Washington DC, 2005.
70. LaPlante KL, Rybak, M.J. Daptomycin. Antimicrobial Therapy and Vaccines. Vol. II: Antimicrobial Agents: www.antimicrobe.org.
71. Zhanel GG, Homenuik K, Nichol K et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64:63-88.
72. Raad I, Darouiche R, Vazquez J et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005; 40:374-80.
73. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003; 37:1298-303.
74. Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, Mercier RC, Rybak MJ. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1998; 42:981-3.
75. Gerber J, Smirnov A, Wellmer A et al. Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob Agents Chemother 2001; 45:2169-72.
76. Giamarellou H ORW, Harris H, Owen S, Porter S, Loutit J. Phase 3 trial comparing 3-7 days of oritavancin vs. 10-14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections (CSSI). In: Program and abstracts of the 43rd ICAAC Conference, Chicago, IL, September 14-17,2003, 2003. American Society of Microbiology.
77. Barrett JF. Recent developments in glycopeptide antibacterials. Curr Opin Investig Drugs 2005; 6:781-90.
78. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005; 49:195-201.
79. Hegde SS, Reyes N, Wiens T et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 2004; 48:3043-50.
80. Stryjewski ME, Chu VH, O'Riordan WD et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006; 50:862-7.
81. Stryjewski ME, O'Riordan WD, Lau WK et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005; 40:1601-7.
82. Aneziokoro CO, Cannon JP, Pachucki CT, Lentino JR. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J Chemother 2005; 17:643-50.
83. Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections. Curr Med Res Opin 2005; 21:1923-6.
84. Anthony S.J. HM, Angelos E, Stratton CW. Clinical Experience with daptomycin in Patients with Orthopedic-Related Infections. 43rd IDSA Annual Meeting 2005. San Francisco, CA, 2005.
85. Yin LY, Lazzarini L, Li F, Stevens CM, Calhoun JH. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 2005; 55:995-1002.
86. Howden BP, Ward PB, Charles PG et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521-8.
87. Fowler VG, Jr., Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.
88. Woods CW, Cheng AC, Fowler VG, Jr et al. Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004; 38:1188-91.
89. Chiang FY, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:3002-4.
90. FDA. Information for Healthcare Professionals: Linezolid (marketed as Zyvox) March 16, 2007, 2007.
91. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 2006; 58:273-80.
92. Kang SL, Rybak MJ. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in ombination against resistant strains of Enterococcus species and Staphylococcus aureus. J Antimicrob Chemother 1997; 39 Suppl A:33-9.
93. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2005; 49:2735-45.
94. Grohs P, Kitzis MD, Gutmann L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:418-20.
95. Jacqueline C, Caillon J, Le Mabecque V et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 2003; 51:857-64.
96. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC, Jr Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38:1700-5.
97. Tsuji BT, Rybak MJ. Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin. Diagn Microbiol Infect Dis 2006; 54:73-7.
98. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48:4665-72.
99. Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. Efficacy of daptomycin in experimental endocarditis due to methicillinresistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:1714-8.
100. Baltch A RW, Bopp L. et al. Killing of methicillin-resistant Staphylococcus aureus by daptomycin, gentamicin, and rifampin, singly and in combination, in broth and in human monocytederived macrophages, with and without GM-CSF and Interferon Activation. Proceedings of the 15th ICAAC Conference, 2005, Abstract E-1741, American Society of Microbiology, Washington, 2005.
101. Allen GP, Cha R, Rybak MJ. In vitro activities of quinupristin-dalfopristin and cefepime, lone and in combination with various antimicrobials, against multidrug-resistant Staphylococci and Enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2002; 46:2606-12.
102. Dailey CF, Pagano PJ, Buchanan LV, Paquette JA, Haas JV, Gibson JK. Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 2003; 47:2655-8.
103. Kang SL, Rybak MJ, McGrath BJ, Kaatz GW, Seo SM. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrob Agents Chemother 1994; 38:2702-9.
104. Zarrouk V, Bozdogan B, Leclercq R et al. Activities of the combination of quinupristin- alfopristin with rifampin in vitroand in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolidelincosamide-streptogramin antibiotics. Antimicrob Agents Chemother 2001; 45:1244-8.
105. Sambatakou H, Giamarellos-Bourboulis EJ, Grecka P, Chryssouli Z, Giamarellou H. In vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates. J Antimicrob Chemother 1998; 41:349-55.
106. Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and timekill kinetic analysis. J Antimicrob Chemother 2006; 57:573-6.
107. Mercier RC, Kennedy C, Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002; 22:1517-23.